Category: Cardiometabolic

—

by

This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → The next-generation obesity pipeline, and why the competitive question is shifting from how much weight a drug removes to what that removal costs in lean mass, tolerability…

Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMIT

—

by

This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → Whether GLP-1 receptor agonists improve hard cardiovascular and kidney outcomes in cardio-renal-metabolic disease, rather than weight alone — read against the SELECT, FLOW and SUMMIT trials. The…

The GLP-1 / incretin landscape — why the question moved from “how much weight?” to “what does it change?”

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The incretin (GLP-1) class is expanding beyond glucose and weight into cardiovascular, kidney and heart-failure indications. In the only two head-to-head trials, the dual agent (tirzepatide)…

The asymmetry in the US cardiovascular-kidney-metabolic standard — widen the diagnosis, narrow the drug threshold

—

by

Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. The four US “definition-setting” societies (AHA, ACC, ADA, ASN) have converged on a single Cardiovascular-Kidney-Metabolic (CKM) syndrome frame that ties heart, kidney and metabolism together, and…

Who names the disease — America’s CKM and Europe’s SMD, two axes of definitional power over metabolic disease

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Two upper-level disease taxonomies are competing over the cardio-renal-metabolic continuum. In the United States, the AHA-led CKM (Cardiovascular-Kidney-Metabolic) Syndrome (2023 advisory → 2026 multisociety guideline).…

Do blood-pressure drugs pay off more the longer you take them? What 51 trials and 357,314 people actually say

Jul 5, 2026

—

by